Know What's Happening in Industry

Quell Takes New Treg Into Clinic After Transplant Study Halt

Quell Therapeutics has launched the phase 1/2 CHILL trial of its autologous CAR‑Treg therapy QEL‑005 in rheumatoid arthritis and systemic sclerosis, after pausing the liver‑transplant program QEL‑001. The multi‑center study will enroll patients in the UK, Germany and Spain, with read‑out expected early next year. QEL‑005 employs a CD19‑directed CAR to modulate B‑cells, T‑cells and inflammatory macrophages, aiming to restore immune balance rather than deplete cells. While seeking a partner for the halted QEL‑001, Quell positions QEL‑005 as a pipeline‑in‑a‑product for complex autoimmunity.